Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

NASDAQ PULM opened at $6.64 on Tuesday. The company has a market capitalization of $24.24 million, a PE ratio of -2.51 and a beta of 0.99. The business’s fifty day moving average is $3.02 and its 200 day moving average is $2.37. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.